• 1
    Hu KQ, Yu AS, Tiyyagura L, et al. Hyperfibrinolyitc activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 15816.
    Direct Link:
  • 2
    Violi F, Ferro D, Basili S, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992; 15: 6726.
  • 3
    Violi F, Alessandri C, Ferro D, et al. Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis. J Clin Pathol 1989; 42: 12469.
  • 4
    Chakrabarti M, Bielawiec JF, Evans JF, et al. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Pathol 1968; 21: 698701.
  • 5
    Brodsky I, Dennis LH. Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time. Am J Clin Pathol 1996; 45: 619.
  • 6
    Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 8396.
  • 7
    Booth NA, Anderson JA, Bennet B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 7727.
  • 8
    Tran-Thang C, Fasel-Felley J, Pralong G, et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 6513.
  • 9
    Marongiu F, Mamusa AM, Mameli C, et al. Alpha2-antiplasmin and disseminated intravascular coagulation in liver cirrhosis. Thromb Res 1985; 37: 28794.
  • 10
    Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 66770.
  • 11
    Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 2307.
  • 12
    Sakharov D, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 1447782.
  • 13
    Wang W, Boffa M, Bajzar L, et al. A study on the mechanism of activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.
  • 14
    Steib A, Gengenwin AS, Freys G, et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 1994; 73: 6458.
  • 15
    Boks AL, Brommer EJ, Schalm SW, et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6: 7986.
  • 16
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 72648.
  • 17
    Violi F, Basili S, Ferro D, et al. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Haemost 1996; 76: 17783.
  • 18
    Mannucci PM. Hemostatic drugs. NEJM 1998; 339: 24553.
  • 19
    Hunt BJ, Segal H. Hyperfibrinolysis. J Clin Pathol 1996; 49: 958.
  • 20
    Teufelsbauer H, Proidl S, Havel M, et al. Early activation of haemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68: 2502.
  • 21
    DelRossi AJ, Cernaianu AC, Botros S, et al. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989; 96: 2730.
  • 22
    Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994; 108: 99106.
  • 23
    Vander Salm TJ, Kaur S, Lancery RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996; 112: 1098107.
  • 24
    Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: A randomized, blinded clinical trial. Anesthesiology 1997; 87: 137380.
  • 25
    Munoz JJ, Birkmeyer NJ, O'Connor GT, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999; 99: 819.
  • 26
    Erstad BL. Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery. Ann Pharmacother 2001; 35: 107584.
  • 27
    Porte RJ, Bontempo FA, Knot EAR, et al. Systemic effects of tPA associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 97884.
  • 28
    Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 76673.
  • 29
    Fanashawe MP, Shore-Lesserson L, Reich DL. Two cases of fatal thrombosis after aminocaproic acid therapy and deep hypothermic circulatory arrest. Anesthesiology 2001; 95: 15257.
  • 30
    Pitts TO, Spero JA, Bontempo FA, et al. Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. Am J Kidney Dis 1986; 8: 4414.
  • 31
    Hayhurst MD. Extensive thrombosis following central venous catheterization – a relationship to antifibrinolytic therapy? S Afr Med J 1983; 63: 797.
  • 32
    McNicol GP, Fletcher AP, Alkjaersig N, et al. The absorption, distribution, and excretion of ɛ-aminocaproic acid following oral or intravenous adminstration to man. J Lab Clin Med 1962; 59: 1524.